Melanotan 1 is the research-chemical name for afamelanotide, an FDA- and EMA-approved alpha-MSH analogue sold as Scenesse, a 16 mg implant given once every 60 days by a healthcare provider. Its approved use is not tanning: it increases pain-free light exposure in adults with erythropoietic protoporphyria, a rare genetic disorder causing severe phototoxic pain from sunlight. Tanning and libido effects are real pharmacological consequences of the drug but were not the outcome the pivotal trials tested, and the self-injected products sold as “Melanotan 1” are a completely different formulation and dosing schedule than the approved implant.
Ask about Melanotan 1
Research snapshot
| Category | Current information |
|---|---|
| Peptide category | Synthetic alpha-MSH analogue, melanocortin receptor agonist |
| Primary research interest | Erythropoietic protoporphyria (approved indication); tanning and libido effects are known pharmacological side consequences, not the tested use |
| Highest available evidence | Tier 1: randomized, placebo-controlled Phase 3 human trials supporting FDA/EMA approval |
| Human research available | Yes, for the approved EPP indication; no trial tested the self-injected cosmetic-tanning regimen |
| Development status | Fully approved pharmaceutical (Scenesse implant) |
| Regulatory status | FDA- and EMA-approved for erythropoietic protoporphyria only; not approved for tanning or cosmetic use |
Technical identity
| Technical property | Information |
|---|---|
| Primary name | Melanotan 1 (research-chemical name for afamelanotide) |
| Alternative names | Afamelanotide, Scenesse (brand), Melanotan I, CUV1647 |
| Peptide sequence | 13-amino acid alpha-MSH analogue with norleucine at position 4 and D-phenylalanine at position 7 |
| Amino-acid length | 13 |
| Molecular formula | C78H111N21O19 |
| Molecular weight | ≈1646.9 g/mol |
| CAS Registry Number | 75921-69-6 |
| PubChem CID | 16197727 |
| Peptide class | Alpha-MSH analogue, melanocortin receptor (MC1R/MC4R) agonist |
| Primary biological target | Melanocortin receptors (MC1R, MC4R) |
| Developer / originator | Clinuvel Pharmaceuticals |
| Development status | Approved prescription drug (16 mg implant, Scenesse) for erythropoietic protoporphyria |
What it is
Melanotan 1 is the research-chemical name for afamelanotide, a synthetic 13-amino-acid analogue of alpha-melanocyte-stimulating hormone (alpha-MSH), with norleucine and D-phenylalanine substituted at positions 4 and 7 to extend its stability compared with the natural hormone. Afamelanotide is FDA-approved, under the brand name Scenesse, and EMA-approved since 2014, but not for tanning or cosmetic use: its approved indication is to increase pain-free light exposure in adults with erythropoietic protoporphyria (EPP), a rare genetic disorder in which sunlight exposure causes severe phototoxic pain.
The approved product is a 16 mg subcutaneous implant, administered by a healthcare provider once every 60 days, not an injectable solution the patient administers at home.
Figures in this table summarize dosing described in the FDA/EMA-approved prescribing information, alongside what circulates online for the unrelated self-injected product. Their inclusion documents what is reported and does not establish what any individual reader should take.
| Product / use | Route | Amount | Frequency | Evidence category |
|---|---|---|---|---|
| Scenesse (approved, for EPP) | Subcutaneous implant, placed by a healthcare provider | 16 mg | Once every 60 days | FDA/EMA-approved prescribing information |
| General tanning/libido use, as commonly circulated online | Subcutaneous injection (self-administered) | 0.5 to 1 mg per dose | Every 1 to 3 days during a loading phase, then less often | Community / vendor reported: a completely different formulation and schedule from the approved implant, never itself studied in a controlled trial |
Potential benefits and research applications
Increased pain-free light exposure in erythropoietic protoporphyria, the FDA- and EMA-approved indication
Randomized, placebo-controlled Phase 3 trials in EPP patients measured pain-free time spent in direct sunlight as the primary endpoint, establishing the basis for approval as Scenesse, a 16 mg implant given once every 60 days.
Evidence: has been shown in randomized, placebo-controlled Phase 3 human trials (Tier 1, published human clinical evidence, FDA- and EMA-approved indication).
Skin tanning and libido effects, real but not the tested outcome
Tanning and libido effects are documented in the EPP trial population as expected pharmacological consequences of MC1R and MC4R agonism, and this mechanism is the entire basis for the drug’s off-label cosmetic-tanning popularity.
Evidence: has been observed as a secondary effect within an approved-indication trial (Tier 1 for the mechanism, but not a tested primary outcome); has not been established as safe or effective for cosmetic tanning as a primary goal, and no trial tested the self-injected regimen used for that purpose.
The evidence behind the approval
Approval rested on randomized, placebo-controlled Phase 3 trials in EPP patients (conducted in the US and Europe), which measured pain-free time spent in direct sunlight as the primary endpoint, alongside safety monitoring for a rare disease population using a drug whose entire mechanism is increased melanin production.
Tanning and libido effects are real pharmacological consequences of MC1R and MC4R agonism, and are documented in the EPP trial population as expected effects of the drug, but they are not the indication the drug is approved for or tested against as a primary outcome.
What is not established
Efficacy or safety for cosmetic tanning or libido enhancement in a population without EPP. No trial reviewed for this entry tested afamelanotide, or the injectable Melanotan I product circulating outside the approved implant, for those uses as a primary endpoint.
Whether the injectable, self-administered products sold as “Melanotan 1” match the composition, purity or stability of the pharmaceutical-grade implant studied in the pivotal trials. A 2026 stability-profiling study found that afamelanotide degrades under a range of storage and light conditions into at least 14 identifiable degradation products, underscoring that formulation and handling affect what the compound actually is at the point of use.
Frequently asked questions
What is Melanotan 1?
Melanotan 1 is the research-chemical name for afamelanotide, an FDA- and EMA-approved alpha-MSH analogue sold as Scenesse for erythropoietic protoporphyria.
How does Melanotan 1 work?
It activates MC1R and MC4R melanocortin receptors, stimulating melanin production, which increases pain-free light tolerance in EPP patients and produces tanning and libido effects as pharmacological side consequences.
What dosage has been studied in humans?
The approved product is a 16 mg subcutaneous implant, administered by a healthcare provider once every 60 days. No trial tested a self-injected solution dosed more frequently.
What dosage commonly circulates online?
Circulating “Melanotan 1” is sold as an injectable solution, 0.5 to 1 milligram, every 1 to 3 days during a loading phase, then less often. This is a completely different formulation and schedule than the approved implant, and it has not itself been studied in a controlled trial.
Has Melanotan 1 been studied in humans?
Yes, in randomized, placebo-controlled Phase 3 trials for its approved EPP indication. No trial tested the self-injected product for cosmetic tanning or libido as a primary endpoint.
Is Melanotan 1 approved for use?
Yes, as Scenesse, for erythropoietic protoporphyria only. It is not approved for tanning or cosmetic use.
What routes of administration are reported?
The approved product is a subcutaneous implant placed by a healthcare provider. Circulating products are self-injected subcutaneous solutions.
Does Melanotan 1 work for tanning?
Tanning is a real pharmacological effect of its mechanism, documented in the approved-indication trial population, but it was not the primary outcome tested, and the self-injected products used for this purpose have not been studied in a controlled trial for that purpose.
What side effects have been reported?
Effects tied to melanocortin receptor activation are expected, including tanning and libido changes. A 2026 stability study found that afamelanotide degrades into at least 14 identifiable degradation products under various storage and light conditions, raising questions about what self-administered, non-pharmaceutical-grade products actually contain.
What remains unknown about Melanotan 1?
Efficacy and safety for cosmetic tanning or libido enhancement outside EPP, since no trial tested that use as a primary endpoint, and whether self-administered injectable products match the composition, purity or stability of the studied pharmaceutical-grade implant.
Bottom line
Melanotan 1 (afamelanotide) is a genuinely FDA- and EMA-approved drug, but for a rare, narrow medical indication, erythropoietic protoporphyria, delivered as a 16 mg implant every 60 days by a healthcare provider. The tanning and libido effects that drive its popularity as a self-injected research peptide are real pharmacological consequences of its mechanism, but they were never the tested outcome, and the self-injected product bears little resemblance to the studied and approved implant.
Sources
- Chawathe A, Sharma N. Investigation of the stability profile of therapeutic alpha-MSH analogue: Insights from liquid chromatography-high resolution mass spectrometry analysis of afamelanotide. J Pharm Biomed Anal 2026;272:117362. 14 degradation products identified under stress conditions. PMID 41547183
- US Food and Drug Administration. SCENESSE (afamelanotide) implant, prescribing information. Approved indication: increase pain-free light exposure in adults with erythropoietic protoporphyria. 16 mg SC implant every 60 days. FDA NDA 210797
Compare Melanotan 1 with related compounds
Research area: Sexual health and melanocortin.